| 2025 | Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC | NEW ENGLAND JOURNAL OF MEDICINE |
| 2025 | Asian Subgroup Analysis of Patients in the Phase 2 DeLLphi-301 Study of Tarlatamab for Previously Treated Small Cell Lung Cancer
| ONCOLOGY AND THERAPY |
| 2025 | Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study
| JOURNAL OF THORACIC ONCOLOGY |
| 2025 | Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study
| JOURNAL OF THORACIC ONCOLOGY |
| 2025 | Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter Trial
| JOURNAL OF THORACIC ONCOLOGY |
| 2025 | Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study
| EUROPEAN JOURNAL OF CANCER |
| 2025 | Evolving roles of MET as a therapeutic target in NSCLC and beyond | NATURE REVIEWS CLINICAL ONCOLOGY |
| 2025 | What Is On the Horizon for the Diagnosis and Treatment of SCLC and Large Cell Neuroendocrine Cancer? | JTO Clinical and Research Reports |
| 2025 | Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells
| NATURE COMMUNICATIONS |
| 2025 | D3S-001 in advanced solid tumors with KRASG12C mutations: a phase 1 trial | NATURE MEDICINE |
| 2025 | Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas | CLINICAL CANCER RESEARCH |
| 2025 | Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| 2025 | Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study
| ANNALS OF ONCOLOGY |
| 2025 | Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy | NEW ENGLAND JOURNAL OF MEDICINE |
| 2025 | Discovery of BBT-176 as a fourth-generation EGFR tyrosine kinase inhibitor | Results in Chemistry |
| 2025 | Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer
| LUNG CANCER |
| 2025 | A Response to the Letter to the Editor: "POSEIDON's Missing Piece: Unanswered Questions on PFS Data in High-Risk Subgroups" | JOURNAL OF THORACIC ONCOLOGY |
| 2025 | Plain language summary of MARIPOSA-2: amivantamab-chemotherapy either with or without lazertinib for treatment of non-small-cell lung cancer
| FUTURE ONCOLOGY |
| 2025 | Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2025 | Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset
| LUNG CANCER |
| 2025 | ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib | JCO PRECISION ONCOLOGY |
| 2025 | Association of thyroid radiation dose with thyroid dysfunction in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy followed by maintenance immunotherapy | LUNG CANCER |
| 2025 | Plain language summary of first-line amivantamab-lazertinib in previously untreated high-risk EGFR-altered non-small-cell lung cancer in MARIPOSA
| FUTURE ONCOLOGY |
| 2025 | Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A
| JOURNAL OF THORACIC ONCOLOGY |
| 2025 | First-Line Mobocertinib Versus Platinum-Based Chemotherapy in Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer in the Phase III EXCLAIM-2 Trial
| JOURNAL OF CLINICAL ONCOLOGY |
| 2025 | Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib
| ANNALS OF ONCOLOGY |
| 2025 | Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC (NORA)
| JOURNAL OF THORACIC ONCOLOGY |
| 2025 | A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer | LUNG CANCER |
| 2025 | Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study
| JOURNAL OF CLINICAL ONCOLOGY |
| 2025 | Osimertinib long-term tolerability in patients with EGFRm NSCLC enrolled in the AURA program or FLAURA study | LUNG CANCER |
| 2025 | A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial | LUNG CANCER |
| 2025 | Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab
| MOLECULAR CANCER THERAPEUTICS |
| 2025 | Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC Reply | NEW ENGLAND JOURNAL OF MEDICINE |
| 2025 | Reply to the Letter to the Editor regarding 'PFS, OS or toxicity: what is the most important factor in the treatment of EGFR-mutated lung cancer?' by T. Nishimura and H. Fujimoto
| ANNALS OF ONCOLOGY |
| 2025 | Population-Adjusted Indirect Treatment Comparisons of Repotrectinib Among Patients with ROS1+ NSCLC
| CANCERS |
| 2025 | The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC
| CELL REPORTS MEDICINE |
| 2025 | Harnessing the Potential of FAP-IL12mut TMEkine for Targeted and Enhanced Antitumor Responses
| MOLECULAR CANCER THERAPEUTICS |
| 2025 | FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004)
| LUNG CANCER |
| 2025 | Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial
| JOURNAL OF THORACIC ONCOLOGY |
| 2025 | The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group
| CANCER RESEARCH AND TREATMENT |
| 2024 | Plain language summary: tarlatamab for patients with previously treated small cell lung cancer
| FUTURE ONCOLOGY |
| 2024 | Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study
| FUTURE ONCOLOGY |
| 2024 | NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
| CANCER DISCOVERY |
| 2024 | ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial | CLINICAL CANCER RESEARCH |
| 2024 | Longitudinal Analyses of Circulating Tumor DNA for the Detection of EGFR Mutation-Positive Advanced NSCLC Progression During Treatment: Data From FLAURA and AURA3 | JOURNAL OF THORACIC ONCOLOGY |
| 2024 | Expression of PD-L1, PD-L2, and inflammatory gene expression profile in locally advanced head and neck squamous cell carcinoma
| ESMO OPEN |
| 2024 | ASO Visual Abstract: Left Upper Division Segmentectomy Compared with Lobectomy for Lung Expansion and Bronchus Tortuosity | ANNALS OF SURGICAL ONCOLOGY |
| 2024 | Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study
| BMC MEDICINE |
| 2024 | Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2024 | Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer
| ONCOLOGIST |
http://orcid.org/0000-0002-5562-270X
(7401747804)
